Trial Profile
Combined Fulvestrant and Anastrozole as Neo-Adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- 18 May 2023 Status changed from active, no longer recruiting to completed.
- 17 May 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.
- 29 Apr 2021 Planned End Date changed from 1 May 2020 to 1 May 2022.